- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04137692
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome
Study Overview
Status
Intervention / Treatment
Detailed Description
As the transporter responsible for basal levels of glucose flux, Glucose transporter 1 (GLUT1) is expressed at low levels in most tissues. In contrast, GLUT1 is very highly expressed on human erythrocytes. Human erythrocytes possess up to 5x105 copies of GLUT1 in their membranes representing almost 5% of total membrane protein. This allows erythrocytes to catalyze glucose transfer at rates three orders of magnitude greater than their capacity to utilize it. It has been proposed that human erythrocytes function in glucose storage, especially when the serum carrying capacity for glucose becomes limiting. If this hypothesis could be validated experimentally, it would be of fundamental importance to the understanding of human physiology.
This proposal also has the potential to uncover a novel therapeutic option for patients with Glucose Transporter Type 1 Deficiency (G1D). Currently, the only treatment for G1D is the ketogenic diet. While the ketogenic diet improves seizures in a fraction of patients, its effects on neurodevelopment and long-term health are poor, so better treatment options for G1D are needed. Because of the hypoglycorrachia (i.e. low cerebrospinal fluid glucose) of G1D patients, the endothelial cells of the blood-brain barrier microvessels have long been assumed to be the primary site of disease pathogenesis. However, most G1D patients also have deficits in GLUT1 levels and glucose uptake in their erythrocytes and a potential contribution of this compartment to disease pathogenesis is likely. GLUT1 deficient mice are not amenable to test the hypothesis because they do not fully recapitulate the clinical presentation of G1D patients and because they exhibit metabolic adaption to G1D. Red blood cell exchange (RBCx) is a safe and cost effective treatment to prevent strokes and vascular abnormalities in patients with sickle cell anemia. RBCx has the potential to dramatically alter the treatment of G1D patients.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or Female
- Age 16 years to 64 years old.
- Diagnosed with genetically-confirmed glucose transporter type 1 disorder
- Patients not currently receiving dietary therapy, including ketogenic diet or other dietary therapy, due to failure of these diets to achieve seizure remission or due to patient preference, including compliance or tolerance issues. Patients currently on Modified Atkins Diet (MAD) and / or taking Medium Chain Triglyceride (MCT) oil are allowed.
Exclusion Criteria:
- Currently on the ketogenic diet or taking triheptanoin (C7) oil
- No genetic confirmation of G1D diagnosis
- Unable to return for follow up visits
- Weak peripheral veins, such that IV placement is contraindicated (required for transfusion)
- Serious chronic medical conditions, such as congestive heart failure, renal failure, liver failure, or any other medical conditions that preclude large volume transfusions.
- Patients currently pregnant or breast-feeding are excluded from participating in this research. Patients who plan on getting pregnant during this research or who are unwilling to use birth control, including abstinence, during the course of this research are also excluded due to safety concerns for the fetus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Red Blood Cell Transfusion
Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
|
The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients.
Two IVs are placed for the purposes of transfusion, one for draw and one for return.
Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in electroencephalogram (EEG)
Time Frame: Baseline, during transfusion, and 60 days after transfusion
|
Change in number of seizures recorded
|
Baseline, during transfusion, and 60 days after transfusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in neuropsychological receptive language test battery
Time Frame: Baseline, immediately after transfusion, and 60 days after transfusion
|
Change in standard scores obtained from the Peabody Picture Vocabulary Test.
|
Baseline, immediately after transfusion, and 60 days after transfusion
|
Change in neuropsychological expressive language test battery
Time Frame: Baseline, immediately after transfusion, and 60 days after transfusion
|
Change in standard scores obtained from the Expressive Vocabulary Test.
|
Baseline, immediately after transfusion, and 60 days after transfusion
|
Change in neuropsychological attention scores
Time Frame: Baseline, immediately after transfusion, and 60 days after transfusion
|
Change in T-scores obtained on the Connors Continuous Performance Test.
Minimum T score is less than 30.
Maximum T score is 90.
Higher T scores for Hit Reaction Time domain indicate slower reaction time while lower scores indicate faster reaction time.
For all other domains (detectability, omissions, commissions, perseverations), higher T scores indicated elevated performance while lower T scores indicate lower performance.
|
Baseline, immediately after transfusion, and 60 days after transfusion
|
Changes in biochemical assay
Time Frame: Baseline, immediately after transfusion, and 60 days after transfusion
|
Number of participants with erythrocyte Glut1 levels that have increased by over 40% from baseline.
|
Baseline, immediately after transfusion, and 60 days after transfusion
|
Change in General Medical & Neurological Examination
Time Frame: Baseline and 60 days after transfusion
|
Change in score of standardized clinical physical exam, which has 12 domains scored either normal or abnormal.
Minimum total score is 0. Maximum total score is 76.
Lower scores are considered more abnormal.
Higher scores indicate a more normal exam and and better outcomes than lower scores.
|
Baseline and 60 days after transfusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juan Pascual, MD, PhD, UT Southwestern Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTSW 122014-010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Transporter Type 1 Deficiency Syndrome
-
University of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect | GLUT1DS1United States
-
Juan PascualNational Institute of Neurological Disorders and Stroke (NINDS)CompletedGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect | GLUT1DS1United States
-
Juan PascualCompletedGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency SyndromeUnited States
-
Juan PascualWithdrawnGlucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency SyndromeUnited States
-
Juan PascualNo longer availableGlucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency SyndromeUnited States
-
University of Texas Southwestern Medical CenterRecruitingGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1 | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport DefectUnited States
-
University of British ColumbiaUltragenyx Pharmaceutical IncUnknownGlucose Transporter Type 1 Deficiency SyndromeCanada
-
University of Texas Southwestern Medical CenterRecruitingGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency Syndrome | Glucose Transporter type1 (GLUT-1) Deficiency | GLUT-1 Deficiency SyndromeUnited States
-
Ultragenyx Pharmaceutical IncCompletedGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)United States, Spain, Australia, France, Israel, Italy, United Kingdom
-
Ultragenyx Pharmaceutical IncAvailableGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Clinical Trials on Red Blood Cell Transfusion
-
Bristol-Myers SquibbActive, not recruitingLower-risk Myelodysplastic SyndromesJapan
-
NHS Blood and TransplantUniversity of York; British Medical Research CouncilTerminatedSickle Cell DiseaseUnited Kingdom
-
Sanquin Research & Blood Bank DivisionsNetherlands: Ministry of Health, Welfare and SportsWithdrawnMyelodysplastic SyndromesNetherlands
-
Hvidovre University HospitalIMK FondenUnknown
-
Fundació Institut de Recerca de l'Hospital de la...UnknownCirrhosis | Portal Hypertension | Upper Gastrointestinal BleedingSpain
-
Mayo ClinicDuke University; Blood Systems Research InstituteCompletedBlood Transfusion ComplicationsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedCancer | SurgeryFrance
-
Australian and New Zealand Intensive Care Research...Not yet recruitingExtracorporeal Membrane Oxygenation Complication | Blood Loss Anemia
-
University Hospital TuebingenGerman Research FoundationCompletedAnemia of PrematurityGermany, Denmark
-
Instituto do CoracaoUnknown